BCG 预刺激后联合一种新型白细胞介素组合可激活 NK 细胞，使其选择性增殖并成为抗肿瘤长效效应细胞

The short-lived nature and heterogeneity of Natural Killer (NK) cells limit the development of NK cell-based therapies, despite their proven safety and efficacy against cancer.

Here, we describe the biological basis, detailed phenotype and function of long-lived anti-tumour human NK cells (CD56 high CD16 + ), obtained without cell sorting or feeder cells, after priming of peripheral blood cells with Bacillus Calmette-Guérin (BCG).

Further, we demonstrate that survival doses of a cytokine combination, excluding IL18, administered just weekly to BCG-primed NK cells avoids innate lymphocyte exhaustion and leads to specific long-term proliferation of innate cells that exert potent cytotoxic function against a broad range of solid tumours, mainly through NKG2D.

Strikingly, a NKG2C + CD57 - FcεRIγ + NK cell population expands after BCG and cytokine stimulation, independently of HCMV serology. This strategy was exploited to rescue anti-tumour NK cells even from the suppressor environment of cancer patients' bone marrow, demonstrating that BCG confers durable anti-tumour features to NK cells.